HN2009003402A - Derivados de 7-alquinil-1,8- naftiridonas y su preparacion - Google Patents

Derivados de 7-alquinil-1,8- naftiridonas y su preparacion

Info

Publication number
HN2009003402A
HN2009003402A HN2009003402A HN2009003402A HN2009003402A HN 2009003402 A HN2009003402 A HN 2009003402A HN 2009003402 A HN2009003402 A HN 2009003402A HN 2009003402 A HN2009003402 A HN 2009003402A HN 2009003402 A HN2009003402 A HN 2009003402A
Authority
HN
Honduras
Prior art keywords
preparation
naftiridonas
alquinil
derivatives
therapeutics
Prior art date
Application number
HN2009003402A
Other languages
English (en)
Inventor
Alam Antonie
Biscarrat Sandrine
Blanc Isabelle
Bono Francoise
Duclos Olivier
Mc Cort Gary
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of HN2009003402A publication Critical patent/HN2009003402A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

SE REFIERE A US COMPOSICION , PRODECIMINETOS DE PREPARARCION Y APLICACION EN TERAPEUTICA
HN2009003402A 2007-06-13 2009-12-11 Derivados de 7-alquinil-1,8- naftiridonas y su preparacion HN2009003402A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0704192A FR2917412B1 (fr) 2007-06-13 2007-06-13 Derives de 7-alkynyl, 1,8-naphthyridones, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
HN2009003402A true HN2009003402A (es) 2012-02-27

Family

ID=38870275

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2009003402A HN2009003402A (es) 2007-06-13 2009-12-11 Derivados de 7-alquinil-1,8- naftiridonas y su preparacion

Country Status (45)

Country Link
US (1) US8470847B2 (es)
EP (1) EP2158201B1 (es)
JP (1) JP5343072B2 (es)
KR (1) KR101517636B1 (es)
CN (1) CN101679427B (es)
AP (1) AP2590A (es)
AR (1) AR066954A1 (es)
AT (1) ATE505469T1 (es)
AU (1) AU2008274099B2 (es)
BR (1) BRPI0814035B1 (es)
CA (1) CA2690337C (es)
CL (1) CL2008001775A1 (es)
CO (1) CO6150150A2 (es)
CR (1) CR11157A (es)
CY (1) CY1111631T1 (es)
DE (1) DE602008006188D1 (es)
DK (1) DK2158201T3 (es)
DO (1) DOP2009000264A (es)
EA (1) EA016939B1 (es)
EC (1) ECSP099791A (es)
ES (1) ES2365073T3 (es)
FR (1) FR2917412B1 (es)
GT (1) GT200900309A (es)
HK (1) HK1141790A1 (es)
HN (1) HN2009003402A (es)
HR (1) HRP20110515T1 (es)
IL (1) IL202640A (es)
JO (1) JO2682B1 (es)
MA (1) MA31567B1 (es)
ME (1) ME00961B (es)
MX (1) MX2009013515A (es)
MY (1) MY157754A (es)
NI (1) NI200900211A (es)
NZ (1) NZ581839A (es)
PA (1) PA8781701A1 (es)
PE (1) PE20090307A1 (es)
PL (1) PL2158201T3 (es)
PT (1) PT2158201E (es)
SI (1) SI2158201T1 (es)
SV (1) SV2009003429A (es)
TN (1) TN2009000483A1 (es)
TW (1) TWI405762B (es)
UA (1) UA96994C2 (es)
UY (1) UY31152A1 (es)
WO (1) WO2009007535A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2917413B1 (fr) 2007-06-13 2009-08-21 Sanofi Aventis Sa Derives de 7-alkynyl-1,8-naphthyridones, leur preparation et leur application en therapeutique
FR2933700B1 (fr) 2008-07-08 2010-07-30 Sanofi Aventis Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
FR2952934B1 (fr) 2009-11-23 2012-06-22 Sanofi Aventis Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
FR2954943B1 (fr) * 2010-01-07 2013-03-01 Sanofi Aventis Derives de pyridino-pyridinones arylsulfonamides, leur preparation et leur application en therapeutique
FR2955109B1 (fr) * 2010-01-08 2012-09-07 Sanofi Aventis Derives de 5-oxo-5,8-dihydro-pyrido[2, 3-d]pyrimidine, leur preparation et leur application en therapeutique
FR2965263A1 (fr) 2010-09-24 2012-03-30 Sanofi Aventis Derives de thienopyridine nicotinamide, leur preparation et leur application en therapeutique
EP2524915A1 (en) 2011-05-20 2012-11-21 Sanofi 2-Amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors
JP5748210B2 (ja) * 2011-05-26 2015-07-15 日本化薬株式会社 複素環化合物の製造方法
HUE035712T2 (en) 2012-07-17 2018-05-28 Sanofi Sa Use of Vegfr-3 inhibitors for the treatment of hepatocellular carcinoma
CN108558869B (zh) * 2018-05-10 2019-04-09 西安培华学院 用于治疗肝癌的化合物及其制剂
CN110981869A (zh) * 2019-12-10 2020-04-10 天津科技大学 一种1,8-双氮杂色酮的合成方法及其在抗糖尿病药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9800921A (es) * 1995-08-02 1998-05-31 Chirotech Technology Ltd Quinolonas y su uso terapeutico.
EP0978516A4 (en) * 1998-01-29 2001-01-10 Suntory Ltd 1-CYCLOALKYL-1,8-NAPHTHYRIDINE-4-ONE DERIVATIVES HAVING PHOSPHODIESTERASE IV INHIBITING ACTIVITY
CA2447765C (en) * 2001-05-24 2011-01-25 Merck Frosst Canada & Co./Merck Frosst Canada & Cie 1-biaryl-1,8-napthyridin-4-one phosphodiesterase-4 inhibitors
JP2008501628A (ja) 2004-06-02 2008-01-24 武田薬品工業株式会社 インドール誘導体およびがんの治療用途
FR2917413B1 (fr) * 2007-06-13 2009-08-21 Sanofi Aventis Sa Derives de 7-alkynyl-1,8-naphthyridones, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
UA96994C2 (ru) 2011-12-26
JO2682B1 (en) 2013-03-03
AR066954A1 (es) 2009-09-23
HRP20110515T1 (hr) 2011-08-31
NI200900211A (es) 2010-07-15
US20100144757A1 (en) 2010-06-10
CN101679427B (zh) 2013-02-20
CY1111631T1 (el) 2015-10-07
AP2010005099A0 (en) 2010-02-28
GT200900309A (es) 2012-01-26
PL2158201T3 (pl) 2011-09-30
JP2010529178A (ja) 2010-08-26
KR20100020000A (ko) 2010-02-19
EA016939B1 (ru) 2012-08-30
WO2009007535A2 (fr) 2009-01-15
IL202640A (en) 2014-01-30
CL2008001775A1 (es) 2009-09-25
MX2009013515A (es) 2010-01-27
CR11157A (es) 2010-03-23
KR101517636B1 (ko) 2015-05-04
CN101679427A (zh) 2010-03-24
FR2917412A1 (fr) 2008-12-19
ECSP099791A (es) 2010-01-29
DK2158201T3 (da) 2011-08-01
EP2158201B1 (fr) 2011-04-13
JP5343072B2 (ja) 2013-11-13
WO2009007535A3 (fr) 2009-04-09
UY31152A1 (es) 2009-01-30
TW200911802A (en) 2009-03-16
DOP2009000264A (es) 2009-12-15
MA31567B1 (fr) 2010-08-02
BRPI0814035A2 (pt) 2020-08-04
PT2158201E (pt) 2011-07-05
EA201070009A1 (ru) 2010-06-30
CA2690337A1 (fr) 2009-01-15
EP2158201A2 (fr) 2010-03-03
PA8781701A1 (es) 2009-01-23
AU2008274099A1 (en) 2009-01-15
ATE505469T1 (de) 2011-04-15
IL202640A0 (en) 2010-06-30
AU2008274099B2 (en) 2013-05-16
MY157754A (en) 2016-07-15
NZ581839A (en) 2011-05-27
ES2365073T3 (es) 2011-09-21
TWI405762B (zh) 2013-08-21
HK1141790A1 (es) 2010-11-19
CA2690337C (fr) 2015-08-11
TN2009000483A1 (fr) 2011-03-31
ME00961B (me) 2012-06-20
US8470847B2 (en) 2013-06-25
FR2917412B1 (fr) 2009-08-21
BRPI0814035B1 (pt) 2021-10-26
PE20090307A1 (es) 2009-04-20
CO6150150A2 (es) 2010-04-20
SI2158201T1 (sl) 2011-07-29
AP2590A (en) 2013-02-04
SV2009003429A (es) 2010-02-05
DE602008006188D1 (de) 2011-05-26

Similar Documents

Publication Publication Date Title
HN2009003402A (es) Derivados de 7-alquinil-1,8- naftiridonas y su preparacion
UY33079A (es) Derivados de difenil -pirazolopiridinas, su preparación y su aplicación en terapeutica
BRPI0906980A2 (pt) Composição de derivados e maleatados
CR20130001A (es) Derivados de indolizina, su procedimiento de preparación y su aplicación en terapéutica
BRPI0817879A2 (pt) Composições e métodos de uso de anticorpos contra esclerostina
SMT201500176B (it) Composizioni e metodi per inibire l'espressione ditranstiretina
BRPI1013421A2 (pt) composição parasticida tópica, e, uso de uma composição
BR112012002331A2 (pt) composição antiviral, composição farmacêutica e uso de quantidade efetiva de composição farmacêutica
SV2009003098A (es) Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina
BRPI0916769A2 (pt) derivados de benzilbenzeno deuterados e métodos de uso
BRPI1014316A2 (pt) composição, e, uso de uma composição
BRPI0813627A2 (pt) Peptídio antimicrobiano, composições e métodos de uso
CO6341476A2 (es) Derivados de piridino-piridinonas, su preparacion y su aplicacion en terapeutica
BRPI0818003A2 (pt) inibidores de csf-1r, composições e métodos de uso
CY1110648T1 (el) Ενωσεις τροπανιου
HN2008001521A (es) Dimeros de derivados de artemisinina, su preparacion y su aplicacion en terapeutica
DK2257618T3 (da) Fremstilling af glykosylerede polypeptider i mikroalger
BRPI0813770A2 (pt) Composição, e, uso de uma composição
BRPI0914793A2 (pt) Composição, e, uso de uma composição
BR112012003148A2 (pt) composição de remoção de oxigênio, artigo,e, uso da composição de remoção de oxigênio
BRPI0918206A2 (pt) derivados de animoéster e composição medicinal destes
FI20096058A0 (fi) Koostumuksia ja niihin liittyviä menetelmiä ja käyttöjä
BRPI0920355A2 (pt) composições farmacêuticas tópicas estáveis de ozenoxacina e uso de ozenoxacina
DK3363857T3 (da) Hybride modstandsreducerende sammensætninger med højt polymerindhold
BRPI0913441A2 (pt) Composição prebiótica e métodos de produção e uso da mesma